BioCentury | Jan 5, 2021
Management Tracks

Habtezion joins Pfizer as CMO; plus moves at Myovant, Sana, Celldex, ObsEva and Cassava

...company Cassava Sciences Inc. (NASDAQ:SAVA) hired James Kupiec as chief clinical development officer. He was CMO at ProMIS Neurosciences Inc....
BioCentury | Dec 11, 2018
Distillery Therapeutics

Neurology

...Biogen Inc. have IONIS-SOD1Rx, an antisense inhibitor of SOD1, in Phase I/II testing for ALS. ProMIS Neurosciences Inc....
BioCentury | Apr 13, 2018
Clinical News

ProMIS identifies new beta amyloid epitope to treat AD

...cSNK, on beta amyloid oligomers and showed that PMN300 bound to cSNK in vitro . ProMIS Neurosciences Inc....
...the university and has mAbs in preclinical development targeting each of the epitopes, including PMN300. ProMIS Neurosciences Inc....
...Ontario University of British Columbia, Vancouver, B.C. Product: PMN300 Business: Neurology Indication: Treat Alzheimer's disease Mary Romeo PMN310 ProMIS Neurosciences Inc. University...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...for disease staging, while most of the beta amyloid tests are intended to diagnose AD. ProMIS Neurosciences Inc....
...in the blood, along with age. At least one company is developing a companion diagnostic: ProMIS Neurosciences Inc....
...Inc. (NYSE:MRK), Kenilworth, N.J. National Institutes for Health, Bethesda, Md. Probiodrug AG (Euronext:PBD), Halle/Saale, Germany ProMIS Neurosciences Inc....
BioCentury | Feb 24, 2017
Financial News

ProMIS Neurosciences completes private placement

...Neurology company ProMIS Neurosciences Inc. (TSX:PMN) raised C$421,728 ($321,905) through the sale of 2.9 million units at C$0.15...
...whole warrant exercisable at C$0.20. Company directors participated in the offering. ProMIS Neurosciences Inc. (TSX:PMN), Toronto, Ontario Alicia Parker ProMIS Neurosciences Inc....
BioCentury | Feb 16, 2017
Financial News

ProMIS Neurosciences completes private placement

...On Feb. 13, neurology company ProMIS Neurosciences Inc. (TSX:PMN) raised C$2.3 million ($1.8 million) through the sale of...
...to purchase 0.5 shares, with each whole warrant exercisable at C$0.20. ProMIS Neurosciences Inc. (TSX:PMN), Toronto, Ontario Alicia Parker ProMIS Neurosciences Inc....
BioCentury | Sep 19, 2016
Financial News

ProMIS Neurosciences completes private placement of units

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date completed: 2016-09-09 Type: Private placement of units Raised: C$523,943 ($399,978) Units: 3.9 million Price: C$0.14 (unit) Shares after offering: 181.7 million Investors: Company management;...
BioCentury | Aug 15, 2016
Financial News

ProMIS Neurosciences completes private placement of units

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date completed: 2016-08-10 Type: Private placement of units Raised: C$1 million ($759,466) Units: 7.4 million Price: C$0.14 (unit) Shares after offering: 177.8 million Investors: Company...
BioCentury | Jul 11, 2016
Financial News

ProMIS Neurosciences proposes private placement of units

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date announced: 2016-06-27 Type: Private placement of units To be raised: Up to C$1 million ($769,000) Units: 7.4 million Price: C$0.14 (unit) Shares outstanding prior:...
BioCentury | May 9, 2016
Financial News

ProMIS Neurosciences completes private placement

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date completed: 2016-05-04 Type: Private placement Raised: C$351,779 ($280,228) Shares: 5.9 million Price: C$0.06 Shares after offering: 170.4 million Note: ProMIS raised C$351,779 ($280,338) in...
Items per page:
1 - 10 of 67
BioCentury | Jan 5, 2021
Management Tracks

Habtezion joins Pfizer as CMO; plus moves at Myovant, Sana, Celldex, ObsEva and Cassava

...company Cassava Sciences Inc. (NASDAQ:SAVA) hired James Kupiec as chief clinical development officer. He was CMO at ProMIS Neurosciences Inc....
BioCentury | Dec 11, 2018
Distillery Therapeutics

Neurology

...Biogen Inc. have IONIS-SOD1Rx, an antisense inhibitor of SOD1, in Phase I/II testing for ALS. ProMIS Neurosciences Inc....
BioCentury | Apr 13, 2018
Clinical News

ProMIS identifies new beta amyloid epitope to treat AD

...cSNK, on beta amyloid oligomers and showed that PMN300 bound to cSNK in vitro . ProMIS Neurosciences Inc....
...the university and has mAbs in preclinical development targeting each of the epitopes, including PMN300. ProMIS Neurosciences Inc....
...Ontario University of British Columbia, Vancouver, B.C. Product: PMN300 Business: Neurology Indication: Treat Alzheimer's disease Mary Romeo PMN310 ProMIS Neurosciences Inc. University...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...for disease staging, while most of the beta amyloid tests are intended to diagnose AD. ProMIS Neurosciences Inc....
...in the blood, along with age. At least one company is developing a companion diagnostic: ProMIS Neurosciences Inc....
...Inc. (NYSE:MRK), Kenilworth, N.J. National Institutes for Health, Bethesda, Md. Probiodrug AG (Euronext:PBD), Halle/Saale, Germany ProMIS Neurosciences Inc....
BioCentury | Feb 24, 2017
Financial News

ProMIS Neurosciences completes private placement

...Neurology company ProMIS Neurosciences Inc. (TSX:PMN) raised C$421,728 ($321,905) through the sale of 2.9 million units at C$0.15...
...whole warrant exercisable at C$0.20. Company directors participated in the offering. ProMIS Neurosciences Inc. (TSX:PMN), Toronto, Ontario Alicia Parker ProMIS Neurosciences Inc....
BioCentury | Feb 16, 2017
Financial News

ProMIS Neurosciences completes private placement

...On Feb. 13, neurology company ProMIS Neurosciences Inc. (TSX:PMN) raised C$2.3 million ($1.8 million) through the sale of...
...to purchase 0.5 shares, with each whole warrant exercisable at C$0.20. ProMIS Neurosciences Inc. (TSX:PMN), Toronto, Ontario Alicia Parker ProMIS Neurosciences Inc....
BioCentury | Sep 19, 2016
Financial News

ProMIS Neurosciences completes private placement of units

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date completed: 2016-09-09 Type: Private placement of units Raised: C$523,943 ($399,978) Units: 3.9 million Price: C$0.14 (unit) Shares after offering: 181.7 million Investors: Company management;...
BioCentury | Aug 15, 2016
Financial News

ProMIS Neurosciences completes private placement of units

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date completed: 2016-08-10 Type: Private placement of units Raised: C$1 million ($759,466) Units: 7.4 million Price: C$0.14 (unit) Shares after offering: 177.8 million Investors: Company...
BioCentury | Jul 11, 2016
Financial News

ProMIS Neurosciences proposes private placement of units

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date announced: 2016-06-27 Type: Private placement of units To be raised: Up to C$1 million ($769,000) Units: 7.4 million Price: C$0.14 (unit) Shares outstanding prior:...
BioCentury | May 9, 2016
Financial News

ProMIS Neurosciences completes private placement

ProMIS Neurosciences Inc. (TSX:PMN), Mississauga, Ontario Business: Neurology, Cancer, Diagnostic Date completed: 2016-05-04 Type: Private placement Raised: C$351,779 ($280,228) Shares: 5.9 million Price: C$0.06 Shares after offering: 170.4 million Note: ProMIS raised C$351,779 ($280,338) in...
Items per page:
1 - 10 of 67